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Abstract
Oncogene addiction postulates that the survival and growth of certain tumor cells is dependent upon the activity of one
oncogene, despite their multiple genetic and epigenetic abnormalities. This phenomenon provides a foundation for molecular
targeted therapy and a rationale for oncogene-based stratification. We have previously reported that the Promyelocytic
Leukemia protein (PML) is upregulated in triple negative breast cancer (TNBC) and it regulates cancer-initiating cell function,
thus suggesting that this protein can be therapeutically targeted in combination with PML-based stratification. However, the
effects of PML perturbation on the bulk of tumor cells remained poorly understood. Here we demonstrate that TNBC cells are
addicted to the expression of this nuclear protein. PML inhibition led to a remarkable growth arrest combined with features of
senescence in vitro and in vivo. Mechanistically, the growth arrest and senescence were associated to a decrease in MYC and
PIM1 kinase levels, with the subsequent accumulation of CDKN1B (p27), a trigger of senescence. In line with this notion, we
found that PML is associated to the promoter regions of MYC and PIM1, consistent with their direct correlation in breast
cancer specimens. Altogether, our results provide a feasible explanation for the functional similarities of MYC, PIM1, and
PML in TNBC and encourage further study of PML targeting strategies for the treatment of this breast cancer subtype.
Introduction
Breast cancer exemplifies the potential of gene expression
profiling to classify the disease into molecular subtypes
[1–3]. However, these classifications do not inform about
the molecular mediators of tumor progression and metas-
tasis in each subtype of breast cancer. To address this
question, we and others have defined genes and pathways
that are relevant to breast cancer progression, metastasis,
and resistance to therapy [4–6]. The Promyelocytic Leu-
kemia protein (PML), the essential component of the PML
nuclear bodies (PML-NBs), induces apoptosis and inhibits
angiogenesis and cell cycle progression in cancer, thus
complying with the definition of a tumor suppressor [7, 8].
Paradoxically, PML exerts a prosurvival role conferring a
selective advantage in chronic myeloid leukemia and spe-
cific solid tumors [6, 9–15]. In breast cancer, PML regulates
aggressiveness and metastatic features through the control
of the stem cell gene, SOX9, and the Hypoxia-inducible
factor 1 alpha (HIF1α) signaling [13, 15]. Moreover, the
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regulation of cancer-initiating cell (CIC) and metastatic
potential is restricted to PML high-expressing estrogen
receptor-negative breast tumors, predominantly triple
negative breast cancer (TNBC).
The concept that the perturbation of a driver cancer gene
can exert an exacerbated tumor suppressive response in
tumor cells is defined as “oncogene addiction” and provides
a rationale for molecular targeted therapy [16]. Senescence
is a stress response that involves a stable cell growth arrest
as well as an adaptive process to reduce energy consump-
tion for cell division or differentiation and therefore assure
the survival and viability of the cell [17, 18]. Senescence is
induced in vitro by different stimuli including DNA
damage, oxidative stress, oncogene activation, mitochon-
drial dysfunction, or chemotherapy [17, 18]. Cyclin-
dependent kinase inhibitor family (CDKi) is a key reg-
ulator of the senescence response, predominantly through
p53-p21 and/or p16-RB axes [17, 18]. To a lesser extent,
CDKN1B (p27) has been reported to participate in the
activation of the senescence response, in conditions where
p21 and/or p16 are not active [19, 20]. Of note, PML is
required for a fully functional senescence response upon
oncogene activation in tumors where it functions as a tumor
suppressor. In addition, the PML-NBs coordinate the acti-
vation of p53 and the formation of the senescence-
associated heterochromatin foci (SAHF) [21–23].
TNBC exhibits increased levels and activity of various
oncogenes, including MYC and PIM1 [24–27]. Impor-
tantly, these genes regulate metabolic and signaling activ-
ities in this breast tumor subtype, and they represent an
attractive therapeutic vulnerability [24, 26–28]. Whereas
similarities exist among the reported activities of MYC,
PIM1, and PML, their functional association remains
obscure. In this study, we demonstrate that TNBC cells that
express high PML levels are addicted to the nuclear protein,
and its targeting elicits a growth suppressive response that
encompasses MYC and PIM1 downregulation and the
activation of p27-dependent senescence.
Results
PML silencing induces senescence and prevents
tumor growth in vivo
The identification of PML as a novel target in aggressive
breast cancer tumors [13, 15] prompted us to investigate the
molecular consequences of its inhibition in an established
cell culture. To this end, we generated and validated three
PML-targeting doxycycline-inducible and two constitutive
short hairpin RNAs (shRNAs) (Fig. 1a and Supplementary
Fig. 1a) [15]. PML silencing triggered a robust morpholo-
gical change in PML-high expressing cells, MDA-MB-231
(Fig. 1b and Supplementary Fig. 1b), characterized by a
significant increase in size (FSC-A) and granularity
(SSC-A) analyzed by FACS (Fig. 1c and Supplementary
Fig. 1c). These changes in morphology were indicative of a
senescence response. Indeed, the evaluation of senescence-
associated β-galactosidase (SA-β-gal) activity in both
inducible and constitutive systems confirmed this notion
(Fig. 1d, e and Supplementary Fig. 1d, e) in MDA-MB-231
cells. Senescence is defined as an irreversible cell cycle
arrest. Indeed, we could confirm the cell cycle arrest upon
PML genetic inhibition, by means of BrdU analysis
(Fig. 1f) and crystal violet cell number assay (Supplemen-
tary Fig. 1f, g) and that it was not due to an increase in
apoptosis (Supplementary Fig. 1h). Of note, arsenic trioxide
(ATO) did not elicit a senescence phenotype (Supplemen-
tary Fig. 1i). This compound exerts a biphasic effect on
PML; first favors the formation of the PML NBs and then
the degradation of PML. Therefore, the inability of ATO to
recapitulate PML silencing could be due to its molecular
mode of action.
We monitored additional features that were reported for
certain types of oncogene-induced senescence [29]. On the
one hand, proteomics analysis of the supernatant of these
cells indicated that PML silencing resulted in a distinct
secretome, without signs of a canonical SASP (senescence-
associated secretory phenotype) (Supplementary Fig. 1j–l
and Supplementary Table 1). On the other hand, we
ascertained the formation of SAHF. We could not confirm
the existence of SAHF neither at the level of chromatin
condensation nor the formation of macroH2A1.1 foci
(Supplementary Fig. 1m). Lamin B1 loss is a senescence-
associated biomarker [30, 31]. We demonstrated that in our
system PML loss induced a decrease in Lamin B1 protein
levels (Supplementary Fig. 1n–o).
Of note, PML regulates oxidative stress responses
[7, 32]. We ruled out that reactive oxygen species (ROS)
elevation drives senescence in our system since PML loss
does not induce its accumulation (Supplementary Fig. 1p).
Breast CIC capacity is reduced upon PML knockdown in
TNBC cells (with high PML expression), as we demon-
strated in limiting dilution assays with MDA-MB-231 cells
[15]. Here, we hypothesized that the activation of senes-
cence would result in a tumor suppressive response in
established tumors, where the contribution of CIC is neg-
ligible. To test this notion, MDA-MB-231 cells were
injected in the flank of immunocompromised mice, and
once the tumors were established (reaching a volume of
25–130 mm3) doxycycline was administered in the food
pellets to induce PML silencing. In agreement with the
response observed in vitro, xenograft growth was curbed
upon PML knockdown (Fig. 1g, h and Supplementary
Fig. 1q–r) and senescence increase was confirmed by means
of p-HP1γ staining (Fig. 1i, j) [33]. Our data suggest that
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PML silencing in a PML-high expressing TNBC cell line
triggers a senescence response with a partial presence of
classical markers of this process.
p27 is the driver in PML loss-induced senescence
Senescence is executed and sustained at the molecular level
through the activation of growth suppressors, including p53
and the cyclin-dependent kinase (CDKs) inhibitors p21,
p16, and p27 [17, 20, 29]. Since MDA-MB-231 cells harbor
loss of p16 and p53 mutation [34, 35], we proposed p27 as a
candidate to drive PML silencing-induced senescence in our
cell system. Importantly, p27 protein levels were increased
upon both inducible (Fig. 2a and Supplementary Fig. 2a)
and constitutive (Supplementary Fig. 2b) PML silencing
with all the shRNA tested in MDA-MB-231 cells. More-
over, we observed that the induction of p27 protein levels
occurred as soon as 2 days following PML inactivation and
it was maintained up to 6 days of PML silencing (Fig. 2b, c
and Supplementary Fig. 2c–f).
The function of p27 is controlled by changes in its levels
along with its compartmentalization within the cell [36]. To
confirm the functionality of accumulated p27 in PML-
silenced cells, we quantified p27 nuclear localization by
immunoflourescence. As predicted, PML silencing elicited
an increase of nuclear p27 in cells with the three inducible
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Fig. 1 PML silencing induces senescence. Effect of doxycycline-
inducible (150 ng ml−1; 3+ 3 days) PML silencing (sh1, sh4, and sh5)
on PML protein expression (a, representative of at least three
experiments), on the morphology (b, representative images, scale bar,
50 μm), on cell size and granularity (c, FACS analysis, sh1 and sh4,
n= 4, sh5, n= 5), on the number of senescent cells (d; n= 3, repre-
sentative images of SA-β-Galactosidase assay, scale bar 50 μm (e)) and
on the number of BrdU positive cells (f, n= 4) in MDA-MB-231 cells.
Impact of doxycycline-inducible PML silencing (sh4) of established
MDA-MB-231 xenografts on PML protein expression (g), on tumor
growth rate represented as the growth rate of each tumor (h, sh4 no
dox, n= 10; sh4 dox, n= 12; growth rate was inferred from the linear
regression calculated for the progressive change in tumor volume of
each individual tumor during the period depicted in Supplementary
Fig. 1p) and on number of senescent cells measured by p-HP1γ
staining (i, sh4 no dox, n= 4; sh4 dox, n= 4); representative images
of p-HP1γ positive cells, scale bar 100 μm (j) of the tumors. Error bars
represent s.e.m. p, p-value (*p < 0.05, **p < 0.01, ***p < 0.001). One-
tailed Student's t-test was used for cell line data analysis (c, d, f) and
one-tailed Mann–Whitney U-test for xenografts (h, i). sh1, sh4, and
sh5: shRNA against PML, dox: doxycycline, SA-β-gal: senescence-
associated beta-galactosidase, BrdU: bromodeoxyuridine, p-HP1γ:
phospho-heterochromatin protein-1 gamma, molecular weight markers
(kDa) are shown to the right
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shRNA tested (Fig. 2d and Supplementary Fig. 2g). Since
the effect of shRNAs was analyzed in a pooled culture, it is
plausible that there would be heterogeneity in PML levels
across cells within the culture dish. We therefore evaluated
whether the increase in nuclear p27 was ascribed to cells
with a profound decrease in PML immunoreactivity. We
established an immunofluorescence score based on previous
studies [6, 15] (PML low= 0–4 dots; PML high=more
than 4 dots per cell nuclei). In line with our previous results,
we observed a significant inverse association between PML
immunoreactivity and p27 nuclear staining (Fig. 2e–g and
Supplementary Fig. 2h). Moreover, the elevated activity of
p27 upon PML silencing was consistent with the increase in
its mRNA levels, the blockade of Retinoblastoma protein
(Rb) phosphorylation and the reduced transcription of
downstream regulated cell cycle-related genes (Fig. 2h, i
and Supplementary Fig. 2i). In agreement with the results
observed in vitro, p27 accumulation was recapitulated upon
PML knockdown in vivo (Fig. 2j).
Our results reveal that PML silencing in TNBC cells with
high expression of the nuclear protein triggers a senescence
response associated to p27 accumulation. To ascertain the
causal contribution of p27 to the execution of the senes-
cence response, we silenced p27 in MDA-MB-231 cells
concomitantly with PML silencing, using inducible (Fig. 3a,
b) or constitutive (Supplementary Fig. 3a) shRNA systems.
Preventing p27 accumulation upon PML loss hampered the
induction of senescence in a dose-dependent manner
according to the potency of the shRNA against p27 (Fig. 3c
and Supplementary Fig. 3b). Our results demonstrate that
PML loss elicits a senescence response mediated by the
upregulation of p27 in PML high expressing TNBC cells.
Although senescence is a major driver of growth arrest,
we noticed that the amount of SA-β-Gal positivity upon
PML silencing was not comparable to the extent of growth
arrest detected (Fig. 1 and Supplementary Fig. 1). Taking
advantage of our capacity to ablate senescence by silencing
p27, we ascertained the contribution of this response to the
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Fig. 2 p27 is induced after PML silencing. a Effect of doxycycline-
inducible (150 ng ml−1; 3+ 3 days) PML silencing (sh4, sh5) on p27
and PML protein expression (representative of at least three experi-
ments) on MDA-MB-231 cells. b, c Quantification of p27 and PML
protein levels along 6 days of doxycycline-inducible PML silencing on
MDA-MB-231 cells (n= 3) with two different shRNAs. d Immuno-
fluorescence quantification of nuclear p27 positive cells upon PML
inducible silencing on MDA-MB-231 cells (n= 4). e–g Immuno-
fluorescence quantification of the correlation of p27 positive cells and
PML levels in these cells (e–f) and representative images of p27 and
PML staining (g) upon doxycycline-inducible PML silencing in MDA-
MB-231 cells (n= 4). h Effect of doxycycline-inducible (150 ng ml−1;
3+ 3 days) PML silencing (sh4) on RB phosphorylation (Ser780)
(representative of three experiments) on MDA-MB-231 cells. i
Expression of p27-related cell cycle genes upon PML inducible
silencing in MDA-MB-231 cells (n= 3). j Impact of doxycycline-
inducible PML silencing (sh4) on p27 and PML protein expression on
established MDA-MB-231 xenografts. Error bars represent s.e.m. p, p-
value (*/$p < 0.05, **/$$p < 0.01, ***/$$$p < 0.001). One-tailed one-
sample t-test (b, c, i) and one-tailed Student’s t-test were used for cell
line data analysis (d–f). sh4 and sh5: shRNA against PML, dox:
doxycycline. #Unspecific band. Molecular weight markers (kDa) are
shown to the right
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cell number reduction. Importantly, the growth arrest
caused by PML silencing was not recovered by blunting
senescence (Fig. 3d and Supplementary Fig. 3c), thus sug-
gesting that an additional mechanism may be involved.
MYC and PIM1 are regulated by PML in TNBC
Our data demonstrate that preventing p27 accumulation is
not sufficient to rescue the growth arrest caused by PML
loss. We reasoned that the mechanism through which
PML was regulating growth arrest, p27 accumulation and
senescence might depend on a larger growth-regulatory
program. Interestingly, the oncogenic axis comprised with
MYC and PIM1 kinase shares many similarities with
PML concerning its activity in TNBC. MYC and PIM1
are upregulated in TNBC [24, 26, 27] and inhibit p27
accumulation and function [37]. In addition, MYC reg-
ulates metabolic functions attributed to PML, including
fatty acid β oxidation [6, 10, 38, 39] and its inhibition
induces cellular senescence in lymphoma, osteosarcoma,
and hepatocellular carcinoma [40]. With this data in mind,
we first evaluated the association of PML, MYC, and
PIM1 in breast cancer. We found a significant direct
correlation in various breast cancer transcriptomics data-
sets. This association was evident in two out of four
datasets for MYC-PML and four out of four for
PIM1-PML, when accounting all breast cancer subtypes
(Supplementary Fig. 4a). Since the effect of these genes is
restricted to tumors that lack hormone receptors, we
refined the analysis by focusing on estrogen receptor (ER)
negative tumors. In this scenario, the correlation was
recapitulated in various datasets (Fig. 4a).
We next aimed at deconstructing the molecular regula-
tion of PML, MYC, and PIM1. First, we monitored the
impact of PML silencing on MYC abundance. As predicted,
inducible PML shRNA activation resulted in a remarkable
decrease in MYC protein and mRNA levels in vitro and
in vivo (Supplementary Fig. 4b–h) in two PML high
expressing cells, MDA-MB-231 and MDA-MB-468. Of
note, in line with our senescence results (Supplementary
Fig. 1i), ATO did not alter the abundance of p27 and MYC
(Supplementary Fig. 4i–j).
We next asked to which extent MYC downregulation
was retained in cells devoid of p27-dependent senescence
response. To address this question, we checked MYC
expression upon PML/p27 double silencing in MDA-MB-
231 cells. The decrease in MYC expression upon PML loss
was not recovered with p27 silencing (Fig. 4b), thus pro-
viding a feasible explanation for the lack of rescue in
growth capacity.
We have previously shown that PML can regulate gene
expression in line with its association with discreet
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promoter regions [15]. Since PML silencing resulted in
reduced MYC mRNA levels (Supplementary Fig. 4d, h), we
interrogated MYC promoter in silico using ENCODE [41].
We found PML among the proteins with highest confidence
DNA-binding score in MYC promoter region (Fig. 4c,
cluster score: 527). We performed chromatin immunopre-
cipitation (ChIP) analysis of ectopically expressed PML and
confirmed that PML is in the vicinity of MYC promoter
(Fig. 4d). To ascertain if MYC silencing recapitulated the
effect of PML inhibition, we used a validated shRNA tar-
geting this oncogene (sh42) [42, 43] and confirmed that
MYC silencing resulted in increased p27 levels (Fig. 4e and
Supplementary Fig. 4k), senescence (Fig. 4f, g) and growth
arrest (Supplementary Fig. 4l).
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In the last few years, an important body of work has
demonstrated that PIM1 is an important partner of MYC
function in prostate cancer and TNBC [24, 26]. Moreover,
PIM1 can regulate MYC transcriptional signature and p27
[24, 26]. We monitored the impact of PML on PIM1
expression and function. PML loss resulted in a decrease
in PIM1 gene expression in two PML high expressing
cells, MDA-MB-231, and MDA-MB-468 (Supplementary
Fig. 4m–n). Importantly, we confirmed that PML is in close
proximity to PIM1 promoter by ChIP analysis (Fig. 4h,
cluster score: 383 in ENCODE). We hypothesized that loss
of PIM1 would further impact on MYC function and
recapitulate the aforementioned PML and MYC phenotype.
We silenced PIM1 using a validated shRNA (sh18) [24] and
corroborated that the targeting of PIM1 led to decrease in
MYC abundance, increase in p27 levels, senescence, and
growth arrest in MDA-MB-231 cells (Fig. 4i–k and Sup-
plementary Fig. 4o–q). Altogether, our results provide
strong support for the role of MYC-PIM1 axis supporting
PML-elicited TNBC growth and preventing the accumula-
tion of p27 and senescence.
PML loss-elicited growth suppression in breast
cancer is selective of high PML expressing TNBC
The inactivation of a single oncogene can compromise the
development and survival of tumor cells despite their
genetic or epigenetic abnormalities [16]. We have pre-
viously reported that high PML levels in TNBC are required
for adequate CIC function [15]. Here, the data presented
support the notion that the bulk of tumor cells in a TNBC
with elevated PML is “addicted” to the expression of the
protein. In turn, acute depletion of the nuclear protein
results in growth arrest and senescence. To ascertain whe-
ther the “addiction” was restricted to TNBC cells, we took
advantage of various breast cancer cell lines belonging to
distinct subtypes with differing levels of PML. A second
TNBC cell line (MDA-MB-468) that presented high levels
of PML protein was compared with ER+ cells [15]
(Fig. 5a). Silencing of PML in MDA-MB-468 cells elicited
a remarkable growth arrest, which was not detected in the
ER+ cells Cama-1 and MCF7 (Fig. 5b and Supplementary
Fig. 5a–c). In line with this notion, Cama-1 and MCF7 cells
did not exhibit neither the reduction in MYC expression nor
the induction of p27-dependent senescence, as compared
with MDA-MB-468 cells (Fig. 5c, d and Supplementary
Fig. 5d–g). Moreover, the morphological changes induced
by the loss of PML were only present in TNBC cells
(Supplementary Fig. 5h). Since PML silencing resulted in
a distinct secretory phenotype (albeit not a canonical
SASP), we monitored the secretome of the ER+ cell line
Cama-1. In agreement with our prior data, unsupervised
clustering based on the secretome was ineffective in seg-
regating experimental conditions according to PML status.
Similarly, principal component analysis and hierarchical
clustering reinforced the notion that Cama-1 are refractory
to PML level perturbation (Supplementary Fig. 5i–k and
Supplementary Table 2).
Discussion
PML has been a paradigmatic tumor suppressor since its
discovery [7, 8, 44]. A variety of molecular activities
directly support its reported capacity to prevent many of
the hallmarks of cancer, including the induction of
apoptosis and the inhibition of proliferation or angio-
genesis [7]. Molecular partners such as p53 have rein-
forced this notion. However, the discovery of tumoral
contexts, where the presence of PML is required has
broadened the picture of the roles of this nuclear protein in
disease. Depletion of PML impairs the self-renewal
activity in the leukemic stem cell from chronic myeloid
leukemia [9, 10]. This phenotype is the consequence of
both cell autonomous (the hyper-activation of mTOR
complex1 and the reduction in PPARδ-fatty acid oxida-
tion activity [9, 10]) and non-cell autonomous activities
(regulation of the mesenchymal stem cell in the leukemic
niche [45]), which trigger symmetric commitment and the
loss of the CIC compartment.
Fig. 4 PML regulates MYC and PIM1 expression in TNBC. a Cor-
relation analysis between PML and MYC (top panels) and between
PML and PIM1 (bottom panels) mRNA levels in ER negative tumor
specimens of the indicated breast cancer datasets. Sample sizes:
Ivshina (n= 34), Lu (n= 49), TCGA (n= 117) and Wang (n= 77). b
p27, MYC, and PML protein levels upon doxycycline inducible
silencing of either p27 or PML or both in MDA-MB-231 cells
(representative of three experiments). c Cluster score of DNA-binding
proteins in MYC promoter region using ENCODE database. d MYC
promoter region abundance in chromatin immunoprecipitation (ChIP)
of exogenous HA-PMLIV using HA-tag antibody in MDA-MB-231
cells after induction with 50 ng ml−1 doxycycline for 3 days (n= 3).
Data were normalized to IgG (negative-binding control). e p27, MYC,
and PML protein levels upon doxycycline inducible silencing of MYC
(sh42) in MDA-MB-231 cells (representative of three experiments).
Effect on the number of senescent cells (n= 3) (f) and representative
images, scale bar 50 μm, (g) upon MYC inducible silencing in MDA-
MB-231 cells. h PIM1 promoter region abundance in chromatin
immunoprecipitation (ChIP) of exogenous HA-PMLIV using HA-tag
antibody in MDA-MB-231 cells after induction with 50 ng ml−1
doxycycline for 3 days (n= 4). Data were normalized to IgG (nega-
tive-binding control). i p27, MYC, PIM1, and PML protein levels
upon doxycycline inducible silencing of PIM1 (sh18) in MDA-MB-
231 cells (representative of three experiments). j–k Effect on the
number of senescent cells (n= 3) and representative images, scale bar
50 μm, (k) upon PIM1 inducible silencing in MDA-MB-231 cells.
Error bars represent s.e.m. p, p-value (*p < 0.05, ***p < 0.001). One-
tailed one sample t-test (d, h) and one-tailed student's t-test (f, j) were
used for cell line data analysis. shC: Scramble shRNA, Dox: dox-
ycycline, SA-β-gal: senescence-associated beta-galactosidase. Mole-
cular weight markers (kDa) are shown to the right
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The regulation of CIC activity was recently translated to
solid tumors. To date, glioma and a subset of breast cancers
exhibit PML-dependent self-renewal activity [14, 15],
whereas other tumors, such as ovarian cancers or some
experimental models of hepatocarcinoma development,
exhibit a broad tumor suppressive response upon PML
inhibition [11, 12]. PML expression is selectively exacer-
bated in a subset of breast tumors (TNBC) [6, 13, 15]. Yet,
we lack basic understanding around the impact of PML on
the function of this cell subtype. In this study, we demon-
strate that PML depletion in the bulk of TNBC cells in
culture and in vivo triggers a tumor suppressive response
consisting on growth arrest and the activation of
senescence.
PML has been previously related to the regulation of the
senescence response [21]. However, the majority of studies
associate PML expression to the execution of this growth
suppressive response upon the activation of oncogenes or
replicative stress [11]. Experimentally, ectopic PML
expression triggers senescence, and, conversely, PML
deletion bypasses the senescence response elicited by the
oncogenic form of RAS, thus enabling transformation [46–
48]. Mechanistically, PML supports p53 activity and par-
ticipates in the formation of SAHF [21]. In turn, PML loss
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Fig. 5 The antiproliferative program elicited by PML loss is restricted
to PML-high expressing TNBC cells. Effect of doxycycline-inducible
(150 ng ml−1; 3+ 3 days) PML silencing (sh4) on PML and p27
protein expression (a, representative of three experiments), on cell
number (b, MDA-MB-468 and Cama-1, n= 3, MCF7, n= 4) and on
the number of senescent cells (c, MDA-MB-468 and Cama-1, n= 3,
MCF7, n= 4; representative images of SA-β-galactosidase positive
cells (d)) in MDA-MB-468, MCF-7, and Cama-1 cells, scale bar 50
μm. Error bars represent s.e.m. p, p-value (*p < 0.05, **p < 0.01, ***p
< 0.001, ns: not significant). One-tailed one sample t-test (b) and one-
tailed Student's t-test were used for cell line data analysis (c). Dox:
doxycycline, SA-β-gal: senescence-associated beta-galactosidase.
Molecular weight markers (kDa) are shown to the right
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bypasses the senescence response. Paradoxically, our results
indicate that, in cancer cells with high dependence on PML
expression, its inhibition also triggers a senescence response
that lacks canonical SASP and SAHF. This phenomenon
might have been overlooked in prior studies due to the lack
of data at the time on the role of PML favoring cancer cell
function in specific tumor subsets. Of note, the activation of
senescence in non-transformed fibroblasts upon PML
depletion adds complexity to already extensive portfolio of
PML activities [49].
Oncogene addiction [16] is perceived as an attractive
opportunity in the era of targeted therapies. Our results are
consistent with PML addiction in TNBC cells, even if this
protein cannot be formally considered an oncogene. The
data produced by us and others [6, 13, 15] argue in favor of
a molecular make up in this subtype of breast cancer that
requires the presence of PML in high doses, as opposed to
estrogen receptor-positive tumor cells. In this regard, the
control of MYC and PIM1 expression by PML provides a
feasible explanation for the accumulation of p27 and the
induction of senescence when PML is silenced. To which
extent the relationship between PML, MYC, and PIM1 is
operative in other tumor types becomes now an exciting
question to address. Since PML lacks a dedicated domain to
recognize and bind discreet DNA sequences, the existence
of yet unidentified PML-interacting transcription factors
that enable this regulatory mode warrants further research.
The results obtained in this study represent a conceptual
leap in how we perceive the role of PML in TNBC, and
suggest that targeting this nuclear protein can be beneficial
at multiple levels, including impairing the CIC function
[15], blunting hypoxia signaling [13], and triggering a
senescence response. The quantification of the relative
relevance of each PML effector pathway in the overall
activity of PML could open new opportunities to apply the
biology of PML-regulated TNBC function for breast cancer
treatment.
Materials and methods
Cell culture
MDA-MB-231, MDA-MB-468, MCF-7, and Cama-1 cell
lines were obtained from the American Type Culture Col-
lection (ATCC, Manassas, VA, USA) or from Leibniz-
Institut—Deutsche Sammlung von Mikroorganismen und
Zellkulturen GmbH (DMSZ) who provided an authentica-
tion certificate. None of the cell lines used in this study was
found in the database of commonly misidentified cell lines
maintained by ICLAC and NCBI Biosample. Cell lines
were routinely monitored for mycoplasma contamination
and quarantined while treated if positive. MDA-MB-231
and MCF-7 cells were maintained in DMEM media, MDA-
MB-468 were maintained in RPMI media, and Cama-1
were maintained in DMEM-F12 media, all supplemented
with 10% (v/v) foetal bovine serum and 1% (v/v) penicillin-
streptomycin.
Generation of stable cell lines
293FT cells were used for lentiviral production. Lentiviral
vectors expressing shRNAs against human PML and p27
from the Mission® shRNA Library were purchased from
Sigma‐Aldrich. Cells were transfected with lentiviral vec-
tors following standard procedures, and viral supernatant
was used to infect cells. Selection was done using pur-
omycin (2 μg ml−1; P8833, Sigma) for 48 h or blasticidin
(10 μg ml−1; Cat. 15205, Sigma) for 5 days. As a control, a
lentivirus with scrambled shRNA (shC) was used. Short
hairpins sequence: shC: CCGGCAACAAGATGAAGAG
CACCAACTCGAGTTGGTGCTCTTCATCTTGTTGTTT
TT; sh1PML (TRCN0000003865): CCGGCAATACAAC
GACAGCCCAGAACTCGAGTTCTGGGCTGTCGTTGT
ATTGTTTTT; sh4PML (TRCN 0000003867): CCGGG
CCAGTGTACGCCTTCTCCATCTCGAGATGGAGAAG
GCGTACACTGGCTTTTT; sh5PML (TRCN 0000003868):
CCGGGTGTACCGGCAGATTGTGGATCTCGAGATCC-
ACAATCTGCCGGTACACTTTTT; sh1p27 (TRCN
0000039928): CCGGGTAGGATAAGTGAAATGGATA
CTCGAGTATCCATTTCACTTATCCTACTTTTTG;
sh2p27 (TRCN 0000039930): CCGGGCGCAAGTGGAA
TTTCGATTTCTCGAGAAATCGAAATTCCACTTGCGC
TTTTTG. sh42MYC (TRCN0000039642): CCGGCCTGA
GACAGATCAGCAACAACTCGAGTTGTTGCTGATCT
GTCTCAGGTTTTTG. sh18PIM1 (TRCN0000010118):
CCGGACATCCTTATCGACCTCAATCCTCGAGGATT
GAGGTCGATAAGGATGTTTTTT.
Sub-cloning of shC, sh1PML, sh4PML, sh5PML, and
sh42myc into pLKO-Tet-On-Puromycin vector was done
introducing AgeI and EcoRI in the 5′end of top and bottom
shRNA oligos respectively (following the strategy provided
by Dr. Dmitri Wiederschain [50], Addgene plasmid:
21915). Sub-cloning of shC, sh1p27, sh2p27, and
sh18PIM1 into pLKO-Tet-On-Blasticidin was done fol-
lowing the same procedure. Puromycin resistance cassette
was replaced by Blasticidin cassette following Gibson
assembly strategy.
Reagents
Doxycycline (Cat. D9891, Sigma) was used at 150 ng ml−1
to induce the expression of shRNA from pLKO-Tet-On
vectors. Doxycycline-mediated inducible shRNA expres-
sion was performed by treating cell cultures for 72 h with
the antibiotic (150 ng ml−1) and then seeding for cellular or
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molecular assays in the presence of doxycycline for three
more days (unless otherwise specified). ATO (Cat. A1010,
Sigma-Aldrich) was prepared at a concentration of 100 mM
in NaOH 1 N and subsequently diluted to 0.1 mM in PBS
for a working solution. ATO was used at 150 nM for 6 days
as indicated in figure legends.
Cell growth analysis and size measurement by FACS
Cell number quantification was done with crystal violet as
reported [5]. For FACS analysis MDA-MB-231 cells were
trypsinized and resuspended in PBS to be analysed based on
their size (FSC) and granularity (SSC) using a BD FACS-
CantoTM II (BD Biosciences) flow cytometer upon PML
doxycycline-inducible silencing. Data represented in Fig. 1c
correspond to the sum of Q1+Q2+Q3 populations
selected as in Supplementary Fig. 1c. Data were analysed
using the FlowJo software; cell populations were selected
for each shRNA (no dox condition) and differences quan-
tified for increasing size and granularity.
Senescence associated-β-galactosidase detection
To quantify the number of senescent cells, constitutive or
inducible PML/MYC/PIM1/p27 silencing cells was per-
formed as described previously and cells were seeded in
24-well plates in duplicate. An overnight incubation with
the senescence detection kit (QIA117, Calbiochem) was
performed and SA-β-Gal activity was revealed and
quantified (three areas per well, more than 200 cells per
condition). The number of senescent cells in each area
was relativized to the number of total cells counted per
area. Cells were seeded in plates or glass cover slips to
acquire images with EVOS® cell imaging station (×20
magnification objective).
Western blotting, immunofluorescence and BrdU
Western blot analysis was carried out as previously
described [5]. Briefly, cells were seeded on six-well plates.
Cell lysates were prepared with RIPA buffer (50 mM
TrisHCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.1% SDS,
1% Nonidet P40, 1% sodium deoxycholate, 1 mM Sodium
Fluoride, 1 mM sodium orthovanadate, 1 mM beta-
glycerophosphate and protease inhibitor cocktail; Roche).
The following antibodies were used for Western blotting:
rabbit polyclonal anti-PML, 1:1000 dilution (Cat:
A301–167A, Bethyl laboratories), mouse monoclonal anti-
p27[Kip1], 1:1000 dilution (Cat: 610242, BD Biosciences),
mouse monoclonal anti-beta-ACTIN, 1:2000 dilution (Cat:
3700, Cell Signaling), rabbit polyclonal Hsp90, 1:2000
dilution (Cat: 4874, Cell Signaling), rabbit polyclonal
c-Myc, 1:1000 dilution (Cat: 13987, Cell Signaling), rabbit
polyclonal PIM1, 1:1000 dilution (ab75776, Abcam), rabbit
polyclonal Lamin B1 (ab133741, Abcam), rabbit mono-
clonal anti-cleaved PARP (Asp214), 1:1000 dilution (Cat:
5625, Cell Signaling), rabbit polyclonal anti-cleaved cas-
pase 3 (Asp175), 1:1000 dilution (Cat: 9661, Cell Signal-
ing), mouse monoclonal anti-α-Tubulin (66031–1-Ig,
Proteintech), 1:2500 dilution, rabbit monoclonal anti-
phospho-Rb (Ser780) 1:1000 dilution (Cat: 9307, Cell
Signaling). After standard SDS-PAGE and Western blotting
techniques, proteins were visualized using the ECL on
iBright™ CL1000 Imaging System (Cat: A32749, Invitro-
gen). Densitometry-based quantification was performed
using ImageJ software. Uncropped scans are provided in
Supplementary Fig. 6.
For immunofluorescence, cells were seeded on glass
cover slips in 24-well plates, cells were fixed with 4%
para-formaldehyde (15 min), PBS (three times wash), 1%
Triton X-100 (5 min), PBS (three3 times wash), 10% goat
serum (1 h) and anti-PML antibody 1:100 dilution (cata-
log A301–167A; Bethyl laboratories), anti-p27[Kip1]
antibody 1:100 dilution (Cat: 610242, BD Biosciences)
and anti-macroH2A1.1 antibody 1:100 (Cat: 12455, Cell
Signaling) were added ON (4 °C) in goat serum. Cover
slips were washed with PBS three times and incubated
with secondary antibodies (anti-rabbit Alexa488, anti-
rabbit Alexa594, anti-mouse Alexa488, and anti-mouse
Alexa594; Invitrogen-Molecular Probes) for 1 h (room
temperature). Cover slips were washed with PBS three
times, and DAPI added to stain nuclei (10 min), followed
by mounting with ProLong™ Gold Antifade Mountant
(Cat: P36930, Invitrogen). Immunofluorescence images
were obtained with AxioImager D1 microscope (Zeiss) or
with a confocal microscopy (Leica SP8) with ×63 objec-
tives. At least three different areas per cover slip were
quantified.
For BrdU analysis cells were seeded as for immuno-
fluoresce. Prior to fixing, cells were incubated in the pre-
sence of BrdU (3 ug ml−1). Cells were fixed with 4% para-
formaldehyde (15 min), PBS (three times wash) and DNA
exposed with 2M HCl (5 min), PBS (3 times wash) and 0,1
M sodium borate. After that, PBS (three times wash), 1%
Triton X-100 (5 min), PBS (three times wash), 10% goat
serum (1 h), and monoclonal anti-BrdU (MoBU-1) antibody
1:100 dilution (Cat: B35128, Invitrogen) was added ON (4 °
C) in goat serum. Cover slips were washed three times with
PBS and incubated with secondary antibodies (anti-mouse
Alexa594; Invitrogen-Molecular Probes) for 1 h (room
temperature). Cover slips were washed three times with
PBS and DAPI added to stain nuclei (10 min), followed by
mounting with ProLong™ Gold Antifade Mountant (Cat:
P36930, Invitrogen). Images were obtained with an AxioI-
mager D1 microscope (Zeiss). At least three different areas
per cover slip were quantified.
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Quantitative real-time PCR
Cells were seeded as for western blot. Total RNA was
extracted from cells using NucleoSpin RNA isolation kit
from Macherey-Nagel (ref: 740955.250). Complementary
DNA was produced from 1 µg of RNA using Maxima™ H
Minus cDNA Synthesis Master Mix (Cat# M1682, Invi-
trogen). Taqman probes were obtained from Applied Bio-
systems. Amplifications were run in a Viia7 or QS6 Real-
Time PCR Systems (Applied Biosystems) using the fol-
lowing probes: PML (Hs00971694_m1, cat: 4331182). For
p27 (CDKN1B), MYC, PIM1, CDK2, CDK4, E2F3,
AURKA, and CDC25A amplification, Universal Probe
Library (Roche) primers and probes were employed (p27,
For: ccctagagggcaagtacgagt, Rev: agtagaactcgggcaagctg,
probe: 39; MYC, For: gctgcttagacgctggattt, Rev: taacgtt-
gaggggcatcg, probe: 66; PIM1, For: atcaggggccaggttttc,
Rev: gggccaagcaccatctaat, probe: 13; CDK2, For: aaagc-
cagaaacaagttgacg, Rev: gtactgggcacaccctcagt, probe 77;
CDK4, For: gtgcagtcggtggtacctg, Rev: aggcaga-
gattcgcttgtgt, probe 25; E2F3, For: ggtttcggaaatgcccttac,
Rev: gatgaccgctttctcctagc, probe 40; AURKA, For: gca-
gattttgggtggtcagt, Rev: tccgaccttcaatcatttca, probe 79;
CDC25A, For: cgtcatgagaactacaaaccttga, Rev:
tctggtctcttcaacactgacc, probe 67). All quantitative PCR with
reverse transcription data presented were normalized using
GAPDH (Hs02758991_g1, cat: 4331182) from Applied
Biosystems as housekeeping.
Mice
Xenograft experiments were carried out following the
ethical guidelines established by the Biosafety and Welfare
Committee at CIC bioGUNE. The procedures employed
were carried out following the recommendations from
AAALAC. Xenograft experiments were performed as pre-
viously described [5], injecting 3·106 cells per tumor, two
injections per mouse, one per flank. All mice (female Hsd:
Athymic Nude-Foxn1 nu/nu) were inoculated at
8–12 weeks of age. Nineteen days post injection, once
tumors were stablished (25–130 mm3), mice were fed with
chow or doxycycline diet (Research diets, D12100402)
until the experimental endpoint.
p-HP1γ immunohistochemistry
After sacrifice, formalin-fixed paraffin embedded xenograft
tissues were stained for p-HP1γ. Tissues were depar-
affinized using the standard procedure and unmasking/
antigen retrieval was performed using pH 6.0 solution for
20 min at 98 °C in water bath. Tissue sections were stained
for p-HP1γ using primary antibody Phospho-HP1γ (Ser83)
(Cat. No: 2600, Cell Signaling technologies, 1:200) and
secondary antibody Biotinylated antibody Anti-Rabbit (BP-
9100, Vector Laboratories, 1:200). This was followed by
Vectastain ABC solution incubation (PK-6100, Vector
laboratories, 1:150) and DAB staining (SK-4105, Vector
laboratories) as per the manufacturer’s protocol. Stained
slides were scanned using Leica Aperio AT2 slide scanner.
The criteria for senescent staining used for quantification
was a very prominent nuclear staining in which the nucleus
was bigger in size and its staining was darker brown than
the other cells.
ChIP
ChIP was performed using the SimpleChIP® Enzymatic
Chromatin IP Kit (Cat #9003, Cell Signaling Technology,
Inc) as reported [15]. DNA quantification was carried out
using a Viia7 Real-Time PCR System (Applied Biosystems)
with SybrGreen reagents and primers that amplify the pre-
dicted PML binding region to MYC promoter
(chr8:128748295–128748695) as follows: left primer:
CCGGCTAGGGTGGAAGAG, right primer: GCTGCTA
TGGGCAAAGTTTC and PIM1 promoter (chr6:
37137097–37137612) as follows: left primer: ACTCCCTC
CGTGACTCATGT, right primer: ACGAGGGTGG
TCTTTCTGTG.
Secretome analysis
Secretomes were prepared as previously described [51].
MDA-MB-231 sh4 PML tet on and Cama-1 sh4 PML tet on
cells were pre-induced with doxycycline (150 ng ml−1) for
3 days. Three 150 cm2 plates where seeded per condition:
4 × 106 cells per plate of non-induced cells and 5 × 106 cells
per plate of doxycycline induced cells. After two days, cell
supernatants were removed and cells were washed five
times: the first two washes were performed with PBS and
the last three were made with serum-depleted DMEM. Cells
were left to grow for 24 h in serum-depleted DMEM.
Doxycicline was maintained (150 ng ml−1). Two biological
replicates, each with three technical replicates were
processed.
After 24 h supernatant was collected and one dish per
condition was trypsinized and counted to check cell number
and PML expression. The supernatant was first spun at
1000 rpm for 5 min followed by filtration through 0.2 μm
filtering bottles. After this, it was concentrated using 10 kDa
Amicons; first, 15 mL Amicons (Ref. UCF901024, Merck)
were used, followed by 0.5 mL Amicons (Ref. UCF501069,
Merck) to get final volumes close to 80 μL. The con-
centrated secretome was frozen at −20 °C until proteomics
analysis. Protein concentration was determined with a
Pierce BCA protein assay kit (Thermo Scientific). All
samples were digested with trypsin in-solution prior to
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analysis by liquid chromatography−mass spectrometry (LC
−MS). Tryptic digests were analysed by shotgun pro-
teomics using an LTQ Velos-Orbitrap mass spectrometer
(Thermo Fisher Scientific, Bremen, Germany). The RAW
files of each MS run were processed using Proteome Dis-
coverer (Thermo Fisher Scientific), and MS/MS spectra
were searched against the human database of Swiss-Prot
using the MASCOT (Matrix Science, London, U.K) algo-
rithm. The results files generated from MASCOT (.DAT
files) were then loaded into Scaffold (Proteome Software,
Portland, OR), resulting in a nonredundant list of identified
proteins per sample achieving a protein false discovery rate
(FDR) under 1.0%, as estimated by a search against a decoy
database.
Secretome statistical analysis
Relative spectral counting-based protein quantification
analysis was performed on the different samples analyzed
using Scaffold. Files containing all spectral counts for each
sample and its replicates were generated and then exported
to R software for normalization and statistical analysis [52].
All statistical computations were done using the open-
source statistical package R. The data were assembled in a
matrix of spectral counts, where the different conditions are
represented by the columns and the identified proteins are
represented by the rows. An unsupervised exploratory data
analysis by means of principal components analysis and
hierarchical clustering of the samples on the SpC matrix
was first performed. Then, the GLM model based on the
Poisson distribution was used as a significance test [52].
Finally the Benjamini and Hochberg multitest correction
was used to adjust the p-values with control on the FDR.
Full information regarding the proteins detected in the
secretome analysis can be found in Supplementary Tables 1
and 2.
ROS analysis
MDA-MB-231 cells with inducible shRNA against PML
(sh4) were pre-induced with doxycycline (150 ng ml−1) for
3 days. Then, cells were seeded in a six-well plate in tri-
plicate (1.5 × 105 cells/well) maintaining the doxycycline
concentration. Two additional wells with non-induced cells
were used for positive and negative ROS controls
respectively.
After 72 h, 10 µM of 2′, 7′-Dichlorofluorescin diacetate
(DCF-DA) (Sigma-Aldrich Ref: 35845) reactive was added
to each well and cells were incubated for 30 min. In the last
5 min of the incubation time, 1 M hydrogen peroxide
(H2O2) was added to the positive control well.
Subsequently, cells were washed with PBS and raised
from plates employing 500 µL of trypLE reactive (Gibco™
ref: 12563–011). After that, cells were washed twice with
abundant PBS to eliminate the excess of DCF-DA reactive
and pellets were re-suspended in 500 µL PBS for FACS
analysis. Samples were analyzed in FACS CANTO II for
green fluorescence.
Datasets
Database normalization
All the datasets used for the data mining analysis were
downloaded from GEO and TCGA, and subjected to
background correction, log2 transformation, and quartile
normalization. In the case of using a pre-processed dataset,
this normalization was reviewed and corrected if required.
Correlation analysis
Pearson correlation test was applied to analyse the rela-
tionship between paired genes. From this analysis, Pearson
coefficient (R) indicates the existing linear correlation
(dependence) between two variables X and Y, giving a value
between +1 and −1 (both included), where 1 is total
positive correlation, 0 is no correlation, and −1 is total
negative correlation. The p-value indicates the significance
of this R coefficient.
Statistical analysis
No statistical method was used to predetermine sample size.
The experiments were not randomized. The investigators
were not blinded to allocation during experiments and
outcome assessment. Data analysed by parametric tests are
represented by the mean ± s.e.m. of pooled experiments
unless otherwise stated. n values represent the number of
independent experiments performed or the number of
individual mice. For each in vitro independent experiment,
technical replicates were used and a minimum number of
three experiments were performed to ensure adequate sta-
tistical power. In the in vitro experiments, normal dis-
tribution was assumed and one sample t-test was applied for
one component comparisons with control and Student’s t-
test for two component comparisons. For in vivo experi-
ments, a non-parametric Mann–Whitney U-test was used.
Two-tailed statistical analysis was applied for experimental
design without predicted result, and one-tail for validation
or hypothesis-driven experiments. The confidence level
used for all the statistical analyses was of 0.95 (alpha value
= 0.05).
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